Search Results

Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days

Authors: Yamada, Yasuhide; Yamamoto, Noboru; Shimoyama, Tatsu; Horiike, Atsushi; Fujisaka, Yasuhito; Takayama, Kyoko; Sakamoto, Terumi; Nishioka, Yuki; Yasuda, Sanae; Tamura, Tomohide

Source: Cancer Science, Volume 96, Number 10, October 2005 , pp. 721-728(8)

Publisher: Blackwell Publishing

Recent progress in the discovery and development of cyclin-dependent kinase inhibitors

Authors: Fischer, Peter M; Gianella-Borradori, Athos

Source: Expert Opinion on Investigational Drugs, Volume 14, Number 4, 1 April 2005 , pp. 457-477(21)

Publisher: Informa Healthcare

Drugging Cell Cycle Kinases in Cancer Therapy

Authors: Blagden, S.; Bono, J. d.

Source: Current Drug Targets, Volume 6, Number 3, May 2005 , pp. 325-335(11)

Publisher: Bentham Science Publishers

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam

Authors: Kesteren, Charlotte; Zandvliet, Anthe; Karlsson, Mats; Mathôt, Ron; Punt, Cornelis; Armand, Jean-Pierre; Raymond, Eric; Huitema, Alwin; Dittrich, Christian; Dumez, Herlinde; Roché, Henri; Droz, Jean-Pierre; Ravic, Miroslav; Yule, S.; Wanders, Jantien; Beijnen, Jos; Fumoleau, Pierre; Schellens, Jan

Source: Investigational New Drugs, Volume 23, Number 3, June 2005 , pp. 225-234(10)

Publisher: Springer

Phase II study of E7070 in patients with metastatic melanoma

Authors: Smyth, J. F.; Aamdal, S.; Awada, A.; Dittrich, C.; Caponigro, F.; Schöffski, P.; Gore, M.; Lesimple, T.; Djurasinovic, N.; Baron, B.; Ravic, M.; Fumoleau, P.; On behalf of the EORTC New Drug Development and Melanoma Groups,

Source: Annals of Oncology, Volume 16, Number 1, 1 January 2005 , pp. 158-161(4)

Publisher: Oxford University Press

Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX

Authors: Abbate F.; Casini A.; Owa T.; Scozzafava A.; Supuran C.T.

Source: Bioorganic and Medicinal Chemistry Letters, Volume 14, Number 1, 5 January 2004 , pp. 217-223(7)

Publisher: Elsevier

Pharmacokinetic Drug–Drug Interaction of the Novel Anticancer Agent E7070 and Acenocoumarol

Authors: van den Bongard H.J.G.D.; Sparidans R.W.; Critchley D.J.P.; Beijnen J.H.; Schellens J.H.M.

Source: Investigational New Drugs, Volume 22, Number 2, April 2004 , pp. 151-158(8)

Publisher: Springer

CDK inhibitors in clinical development for the treatment of cancer

Authors: Fischer P.M.; Gianella-Borradori A.

Source: Expert Opinion on Investigational Drugs, Volume 12, Number 6, 1 June 2003 , pp. 955-970(16)

Publisher: Informa Healthcare

Indisulam: an anticancer sulfonamide in clinical development

Author: Claudiu T Supuran

Source: Expert Opinion on Investigational Drugs, Volume 12, Number 2, 1 February 2003 , pp. 283-287(5)

Publisher: Informa Healthcare

New Analogues of the Anticancer E7070: Synthesis and Pharmacology

Authors: Laconde G.; Pommery N.; Depreux P.; Berthelot P.; Hénichart J.-P.

Source: Journal of Enzyme Inhibition and Medicinal Chemistry, Volume 18, Number 2, April 2003 , pp. 89-94(6)

Publisher: Informa Healthcare

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)

Authors: Terret C.; Zanetta S.; Roche H.; Schellens J.H.M.; Faber M.N.; Wanders J.; Ravic M.; Droz J.P.

Source: European Journal of Cancer, Volume 39, Number 8, May 2003 , pp. 1097-1104(8)

Publisher: Elsevier

Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of the novel anticancer agent E7070 in four phase I studies

Authors: van Kesteren, CH.; Mathôt, R. A. A.; Raymond, E.; Armand, J. P.; Dittrich, CH.; Dumez, H.; Roché, H.; Droz, J. P.; Punt, C.; Ravic, M.; Wanders, J.; Beijnen, J. H.; Fumoleau, P.; Schellens, J. H. M.

Source: British Journal of Clinical Pharmacology, Volume 53, Number 5, May 2002 , pp. 553P-553P(1)

Publisher: Blackwell Publishing

Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide)

Authors: van Kesteren, Charlotte; Mathôt, R. A. A.; Raymond, E.; Armand, J. P.; Fumoleau, P.; Punt, C.; Ravic, M.; Wanders, J.; Beijnen, J. H.; Schellens, J. H. M.

Source: British Journal of Clinical Pharmacology, Volume 54, Number 5, November 2002 , pp. 463-471(9)

Publisher: Blackwell Publishing

Combination of novel sulfonamide anticancer drug, E7070, with CPT-11 ''antitumor effect and synergistic mechanism''

Source: European Journal of Cancer, Volume 38, Supplement 7, November 2002 , pp. 17-18(2)

Publisher: Elsevier

Phase II study of E7070 in patients with metastatic melanoma (stage IV)

Source: European Journal of Cancer, Volume 38, Supplement 7, November 2002 , pp. 50-50(1)

Publisher: Elsevier

Synthesis and biological evaluation of N-(7-indolyl)-3-pyridinesulfonamide derivatives as potent antitumor agents

Authors: Owa T.; Yoshino H.; Okauchi T.; Okabe T.; Ozawa Y.; Hata Sugi N.; Yoshimatsu K.; Nagasu T.; Koyanagi N.; Kitoh K.

Source: Bioorganic and Medicinal Chemistry Letters, Volume 12, Number 16, 19 August 2002 , pp. 2097-2100(4)

Publisher: Elsevier

Corrigendum to 'E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo' Eur. J. Cancer 2001, 37, 2275-2282. Y. Ozawa, N.H. Sugi, T. Nagasu, T. Owa, T. Watanabe, N. Koyanagi, H. Yoshino, K. Kitoh, K. Yoshimatsu

Author: Ozawa Y.

Source: European Journal of Cancer, Volume 38, Number 5, March 2002 , pp. 736-736(1)

Publisher: Elsevier

Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG)

Authors: Punt C.J.A.; Fumoleau P.; Walle B.v.d.; Faber M.N.; Ravic M.; Campone M.

Source: Annals of Oncology, Volume 12, Number 9, September 2001 , pp. 1289-1293(5)

Publisher: Springer

Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells

Authors: Fukuoka K.; Usuda J.; Iwamoto Y.; Fukumoto H.; Nakamura T.; Yoneda T.; Narita N.; Saijo N.; Nishio K.

Source: Investigational New Drugs, Volume 19, Number 3, August 2001 , pp. 219-227(9)

Publisher: Springer

E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo

Authors: Ozawa¹ Y.; Sugi¹ N.H.; Nagasu T.; Owa T.; Watanabe T.; Koyanagi N.; Yoshino H.; Kitoh K.; Yoshimatsu K.

Source: European Journal of Cancer, Volume 37, Number 17, 2001 , pp. 2275-2282(8)

Publisher: Elsevier